Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial (Q39696947)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

14 September 2017

Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial (English)

1 reference

Europe PubMed Central

14 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

diabetic retinopathy

1 reference

based on heuristic

inferred from title

diabetic macular edema

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

Diabetic Retinopathy Clinical Research Network

7

object named as

Diabetic Retinopathy Clinical Research Network

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

Adam R Glassman

6

object named as

Adam R Glassman

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

5

object named as

Lee M Jampol

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

Neil M. Bressler

4

object named as

Neil M Bressler

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

author name string

David W Hutton

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

language of work or name

0 references

publication date

9 June 2016

1 reference

Europe PubMed Central

14 September 2017

JAMA Ophthalmology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

134

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

888-896

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

Health care economic analyses and value-based medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What is the price of life and why doesn't it increase at the rate of inflation?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic impact of visual impairment and blindness in the United States.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of treatment of diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27280850

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1001/JAMAOPHTHALMOL.2016.1669

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6648661&resulttype=core&format=json

15 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39696947&oldid=2088921579"